The FARAPULSE PFA System now approved for pulmonary vein and posterior wall ablation in patients with persistent atrial fibrillation MARLBOROUGH, Mass., July 7, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the instructions for use (IFU) labeling for the FARAPULSE™ Pulsed Field Ablation (PFA) System. The updated labeling now includes approval for...Read more
Fifth-generation da Vinci surgical system approved for use in Europe across multiple procedures SUNNYVALE, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced today that the da Vinci 5 Surgical System has received CE mark approval for adult and pediatric use in Europe for minimally invasive endoscopic...Read more
Streamlining total ankle replacement with data-driven implants and surgical flexibility PORTAGE, Mich. / Jun 25, 2025 / Business Wire / Stryker (NYSE:SYK), a global leader in medical technologies, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Incompass® Total Ankle System, an implant intended for patients with ankle joints damaged by severe rheumatoid, post-traumatic, or degenerative...Read more
Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach Positions Illumina to achieve growth in a large, expanding market Illumina and SomaLogic have partnered in proteomics co-development since late 2021 SAN DIEGO, June 23, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today it has entered into a definitive agreement with Standard BioTools...Read more
Clareon PanOptix Pro has half the light scatter of Clareon PanOptix1-3,*,** PanOptix Pro provides an unprecedented 94% light utilization, compared to a theoretical maximum utilization of 96% for diffractive optics1-4,*,**,† Clareon PanOptix Pro provides more uninterrupted light distribution across the full visual range, and is designed for better image contrast1,††,‡ TORONTO / Jun 20, 2025 / Business Wire / Alcon (SIX/NYSE: ALC), the...Read more
New offering delivers convenient, comprehensive lab testing solutions for functional medicine, integrative medicine and primary care providers BURLINGTON, N.C., June 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Labcorp Whole Health Solutions to support the growing needs of functional medicine, integrative medicine and primary care...Read more
The test, run on Abbott's portable i-STAT® Alinity® instrument, uses whole blood to help evaluate patients with a suspected mild traumatic brain injury (mTBI), otherwise known as concussion The test produces lab-quality results in 15 minutes Clinicians can get a result at the patient's bedside, making the test accessible at urgent care clinics and healthcare settings outside of the hospital emergency room The test can be used to help...Read more
RESEARCH TRIANGLE PARK, N.C. / Jun 11, 2025 / Business Wire / IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, unveils AI agents at GTC Paris. IQVIA’s new custom-built AI agents using NVIDIA technology are designed to enhance workflows and accelerate insights for life sciences. These live applications of agentic...Read more
Dexcom G7 sensor integration offers more customers the ability to manage diabetes from their iPhone, for additional convenience ACTON, Mass. / Jun 10, 2025 / Business Wire / Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology, is excited to announce that the Omnipod® 5 App for iPhone is now compatible with the Dexcom G7 Continuous Glucose Monitoring (CGM) System. With this latest integration, the...Read more
Kendall DL™ Multi System simplifies patient monitoring, drives efficiencies for providers DUBLIN, Ohio, June 4, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today the U.S. launch of its multi-parameter, single-patient use monitoring cable and lead wire system that enables the continuous monitoring of cardiac activity, blood oxygen level and temperature with one point of connection. The new Kendall DL™ Multi System...Read more
MARLBOROUGH, Mass. / Jun 02, 2025 / Business Wire / SCIEX, a global leader in life science analytical technologies and operating company of Danaher Corporation (NYSE: DHR), announces three software ecosystem enhancements at ASMS. These developments will present new ways to acquire data, new standards for performance, and new practices to extract elevated insights, all supporting the theme that “all science is data science now.” The new...Read more
MARLBOROUGH, Mass. / Jun 02, 2025 / Business Wire / SCIEX, a global leader in life science analytical technologies and operating company of Danaher Corporation (NYSE: DHR), and Evosep Biosystems, a global leader in proteomics solutions, enter a reseller agreement to co-sell SCIEX mass spectrometry systems with the newly announced Evosep Eno, for standardized high-throughput proteomics. The reseller agreement empowers researchers to...Read more
New test offerings target solid tumors and hematologic malignancies Enhanced biopharma services support accelerated clinical trials and companion diagnostic development BURLINGTON, N.C., May 30, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the expansion of its precision oncology portfolio. The additions include new test offerings for solid...Read more
Danaher has entered a partnership with AstraZeneca to scale precision medicine, including developing the next generation of AI-powered diagnostics This partnership aims to create a framework for rapid diagnostics research, development and commercialization Danaher, through its Centers for Enabling Precision Medicine, will provide support in all aspects of the development cycle across diagnostic modalities WASHINGTON, May 29, 2025...Read more
New AI algorithm accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome at scale for the first time SAN DIEGO, May 29, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today unveiled PromoterAI, a new AI algorithm that accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome. A study published today in Science illustrates how this deep...Read more
In pivotal Phase 3 trials, TRYPTYR demonstrated rapid natural tear production as early as Day 11-2 TRYPTYR is a first-in-class TRPM8 receptor agonist that rapidly stimulates natural tear production in patients with Dry Eye Disease (DED)3 Approximately 38 million individuals in the U.S. are living with DED, yet less than 10% of diagnosed patients are being treated with a prescription product4 GENEVA / May 28, 2025 / Business Wire /...Read more
Agilent delivers strong quarter, enabled by Ignite Transformation Highlights Revenue of $1.67 billion for the second quarter ended April 30, 2025, representing growth of 6.0% reported and up 5.3% on a core(1) basis compared with the second quarter of 2024. GAAP net income of $215 million; earnings per share (EPS) of $0.75, down 29% from the second quarter of 2024. Non-GAAP(2) net income of $373 million; EPS of $1.31, up 7% from the...Read more
FRANKLIN LAKES, N.J., May 28, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced plans to initiate a patient data registry for the Rotarex™ Atherectomy System to measure real-world outcomes for patients with peripheral artery disease (PAD). Known as "XTRACT," this prospective, multi-center, single-arm, post-market registry study will assess the...Read more
The Tendyne system replaces mitral valves that are not functioning properly due to a buildup of calcium in the base of the valves, known as severe mitral annular calcification (MAC) Tendyne offers a new treatment option for patients who are not candidates for open-heart surgery or mitral repair This approval expands Abbott's portfolio of minimally invasive structural heart therapies in the U.S. ABBOTT PARK, Ill., May 27, 2025...Read more
Setting new standards for intelligent mass detection, sensitivity, and sustainability SANTA CLARA, Calif. / May 27, 2025 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced the launch of its latest innovation in liquid chromatography (LC)-mass detection: the Agilent InfinityLab Pro iQ Series. This groundbreaking series includes the InfinityLab Pro iQ and the InfinityLab Pro iQ Plus, each tailored with distinct...Read more
Building momentum in key franchises including Pulsed Field Ablation, TAVR, Cardiac Rhythm Management, Diabetes, Spine, and Neuromodulation GALWAY, Ireland, May 21, 2025 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its fourth quarter (Q4) and fiscal year 2025 (FY25), which ended April 25, 2025. Q4 Key Highlights Q4 revenue of $8.9 billion increased 3.9% as...Read more
FRANKLIN LAKES, N.J., May 21, 2025 /PRNewswire/ -- First-of-their-kind studies published in The Lancet Oncology1 and Cancer Medicine2 provide new data showing that cancer patients in both hospital and outpatient settings are at a substantially higher risk of developing antimicrobial resistant (AMR) infections compared to all other non-cancer patients. Key Takeaways: The studies, led by the Cancer and AMR Consortium, which...Read more
Enables intense focus on highest margin growth drivers where Medtronic has leading core competencies Leading, scaled, direct-to-consumer Diabetes business poised to become standalone company; only company with a complete ecosystem to address intensive insulin management GALWAY, Ireland, May 21, 2025 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced its intent to separate its Diabetes...Read more
Stryker's first basivertebral nerve ablation system targets the basivertebral nerve to provide relief from chronic* vertebrogenic low back pain. PORTAGE, Mich., May 19, 2025 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced that its OptaBlate basivertebral nerve ablation system (OptaBlate BVN) received 510(k) clearance from the U.S. Food and Drug Administration. OptaBlate BVNA is used in a...Read more
N of 1 therapy uniquely developed, on demand, for infant with life-threatening rare metabolic disorder in six months Results published in The New England Journal of Medicine and showcased at American Society of Gene & Cell Therapy Annual Meeting FARGO, N.D. & CORALVILLE, Iowa / May 15, 2025 / Business Wire / Aldevron, a global leader in the production of DNA, RNA and protein, together with Integrated DNA Technologies (IDT), a...Read more
New data reveal a 78% reduction in cardiovascular disease-related hospitalizations for people living with Type 1 diabetes with prior severe low blood sugar episodes.1 This significant decrease is linked to the use of Libre biowearable technology compared to traditional blood glucose monitors.1 Results also show a reduction in hospitalization for cardiovascular complications in adults with Type 2 diabetes on insulin using Libre...Read more
Full year fiscal 2025 revenue from continuing operations increased 6%; constant currency organic revenue growth was 6% Full year fiscal 2025 as reported diluted EPS from continuing operations increased to $6.16; adjusted EPS per diluted share increased to $9.22 Fiscal 2026 outlook provided DUBLIN, IRELAND, May 14, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its...Read more
First-quarter 2025 sales of $2.5 billion, in line on a reported basis, or up 3% constant currency1 (cc), versus first-quarter 2024 First-quarter 2025 diluted EPS of $0.70; core diluted EPS2 of $0.73 Generated $384 million cash from operations and $278 million free cash flow3 Dividend of CHF 0.28 per share approved by shareholders at the Annual General Meeting on May 6, 2025 Launched rich pipeline of innovative products, including...Read more
Building on reputation for unparalleled performance, latest software delivers even greater accuracy, with 30% improvement in structural variant calling New features include easy-to-use oncology apps, enhanced multiomics pipelines, and AWS F2 support enabling faster turnaround times SAN DIEGO, May 13, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced the launch of DRAGEN™ version 4.4 software (v4.4), the industry's...Read more
New BD FACSDiscover™ A8 Cell Analyzer Brings Leading-Edge Capabilities to Wider Range of Scientists across Academia and Biopharma FRANKLIN LAKES, N.J., May 13, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the global commercial launch of the world's first cell analyzer featuring breakthrough spectral and real-time cell imaging technologies, enabling more...Read more
Core Illumina revenue of $1.04 billion for Q1 2025, down 1% from Q1 2024 (flat on a constant currency basis) GAAP operating margin of 15.8% and non-GAAP operating margin of 20.4% for Q1 2025 GAAP diluted EPS of $0.82 and non-GAAP diluted EPS of $0.97 for Q1 2025 Cash provided by operations of $240 million and free cash flow of $208 million for Q1 2025 For fiscal year 2025, we expect: Core Illumina revenue to decline between (1%)...Read more
Revenue of $3,829 million GAAP Net Income of $249 million, Adjusted EBITDA of $883 million GAAP Diluted Earnings per Share of $1.40, Adjusted Diluted Earnings per Share of $2.70 R&D Solutions quarterly bookings of $2.1 billion, resulting in trailing-twelve-month bookings of $9.7 billion and a trailing-twelve-month book-to-bill ratio of 1.14x R&D Solutions contracted backlog of $31.5 billion, up 4.8 percent year-over-year TAS...Read more
First quarter net sales of $1.909 billion increased 1.1% and 2.3% on a constant currency1 basis First quarter diluted earnings per share were $0.91; adjusted1 diluted earnings per share were $1.81 Company updates full-year 2025 reported revenue guidance to include the Paragon 28 acquisition and currency expectations, and full-year 2025 adjusted1 earnings per share guidance to include Paragon 28, currency and the impact from current...Read more
SAN DIEGO / May 01, 2025 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2025. First Quarter 2025 Financial Highlights: Revenue grew 12% year-over-year to $1.036 billion on a reported basis and 14% year-over-year on an organic1 basis. U.S. revenue grew 15% and international revenue grew 7% on a reported basis and 12% on an organic1 basis, all on a...Read more
Portage, Michigan, May 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2025: First Quarter Results Reported net sales increased 11.9% to $5.9 billion Organic net sales increased 10.1% Reported operating income margin of 14.3% Adjusted operating income margin(1) increased 100 bps to 22.9% Reported EPS decreased 17.6% to $1.69 Adjusted EPS(1) increased 13.6% to...Read more
First real-world dataset with integrated clinical and multiomic insights from 25,000 patients treated with GLP-1 therapies Dataset will advance development of GLP-1 therapies in new indications and accelerate discovery of novel drug targets in patients who are unresponsive to therapies SAN DIEGO, May 1, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), and Ovation.io, Inc., an organization dedicated to building...Read more
SUNNYVALE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced today that the U.S. Food and Drug Administration (FDA) cleared the da Vinci Single Port (SP) surgical system for transanal local excision/resection, a form of minimally invasive surgery performed through a natural orifice to avoid abdominal surgical...Read more
SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced it has acquired VirtuOx, a leading independent diagnostic testing facility (IDTF) for sleep, respiratory, and cardiac conditions. The acquisition reflects Resmed’s commitment to improving the way care is delivered—by making it more accessible, more...Read more
SANTA CLARA, Calif. / May 01, 2025 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced release of the new Seahorse XF Flex Analyzer, a high-performance, 24-well system designed to expand real-time metabolic analysis into optimized 3D tissue and organoid workflows, along with dedicated consumables and kit. Metabolism is vital for cellular functions, driving energy production and essential processes such as biosynthesis,...Read more
Transforming Care for Severe AS Patients IRVINE, Calif. / May 01, 2025 / Business Wire / Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for severe aortic stenosis (AS) patients without symptoms, marking the first FDA approval for TAVR in asymptomatic patients. Approval of the SAPIEN 3...Read more
First-quarter sales from continuing operations of $2.63 billion increased 5% on both a reported and operational basis, exceeding the company’s previously issued guidance1,2 First-quarter U.S. GAAP3 diluted earnings per share (EPS) from continuing operations of $0.13; adjusted diluted EPS from continuing operations of $0.55, exceeding the company’s previously issued guidance Baxter increases bottom end of previous range for full-year...Read more
Revenue was flat at $54.9 billion; revenue increased 19% excluding the impact of the previously communicated customer contract expiration GAAP1 operating earnings were $730 million; GAAP diluted EPS was $2.10 Non-GAAP operating earnings increased 21% to $807 million, driven by segment profit growth across all of the company's operating segments; non-GAAP diluted EPS increased 13% to $2.35 Fiscal year 2025 non-GAAP EPS guidance2...Read more
Revenue of $5.3 billion increased 4.5% as reported, 6.0% currency-neutral and 0.9% organic GAAP and adjusted diluted EPS of $1.07 and $3.35, respectively Company updates full-year fiscal 2025 guidance and provides estimated tariff impact FRANKLIN LAKES, N.J., May 1, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2025...Read more
Highlights Net business wins in the quarter of $2,022 million; a net book to bill in the quarter of 1.01. Closing backlog of $24.7 billion, an increase of 0.3% on quarter four 2024 and 6.0% on quarter one 2024. Quarter one revenue was $2,001.3 million and quarter one adjusted EBITDA was $390.7 million or 19.5% of revenue. GAAP net income for the quarter was $154.2 million or $1.90 per diluted share. Quarter one adjusted net income...Read more
Collaboration brings together FreeStyle Libre® Systems, the world's leading continuous glucose monitoring technology (CGM)1 with Epic, a healthcare software company, to streamline access to CGM data for healthcare organizations Integration empowers U.S. clinicians to enhance patient care by incorporating Libre's data directly into their workflows ABBOTT PARK, Ill., April 29, 2025 /PRNewswire/ -- Abbott (NYSE: ABT), the global leader...Read more
Updates Full-Year Guidance Results from Operations for first quarter 2025 versus first quarter last year: Revenue: $3.35 billion versus $3.18 billion Diluted EPS: $2.52 versus $2.69 Adjusted EPS: $3.84 versus $3.68 Reaffirmed Revenue and Free Cash Flow guidance, raised midpoint of adjusted EPS: Revenue guidance of 6.7% to 8.0% Adjusted EPS range of $15.70 to $16.40; midpoint raised $0.05 Free Cash Flow of $1.10 billion...Read more
One-year clinical trial data for the next-generation, investigational, Sphere-360™ single-shot PFA catheter show impressive safety, performance, and efficiency results for paroxysmal Afib Dual-energy (RF/PF), focal Sphere-9™ catheter demonstrates efficacy for linear ablation in persistent AFib Medtronic continues legacy of leadership in innovation, showcasing arrhythmia management portfolio at Heart Rhythm Society annual...Read more
Long-term data from the Volt CE Mark Study show strong results out to 12 months in patients receiving pulsed field ablation (PFA) therapy with the Volt™ PFA System The 12-month results of the Volt CE Mark Study confirm the long-term safety and efficacy of the Volt PFA System The data were presented at the 2025 Heart Rhythm Society (HRS) annual meeting ABBOTT PARK, Ill., April 26, 2025 /PRNewswire/ -- Abbott (NYSE: ABT)...Read more
Largest multi-center prospective Investigational Device Exemption (IDE) study for multi-port robotic-assisted urologic surgery in the U.S. presented as a late-breaker at the American Urologic Association annual meeting Company confirms Hugo RAS system submission to the U.S. Food and Drug Administration GALWAY, Ireland and LAS VEGAS, April 26, 2025 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare...Read more
Adding to the Medtronic portfolio of catheter-based lead solutions, the novel OmniaSecure defibrillation lead allows for precise delivery and placement in the right ventricle Heart Rhythm 2025: Late-breaking clinical study results evaluating the OmniaSecure lead for investigational use in the LBBAP location show high defibrillation success GALWAY, Ireland and SAN DIEGO, April 25, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT),...Read more
Trial achieves positive results in the treatment of persistent atrial fibrillation MARLBOROUGH, Mass. and SAN DIEGO, April 24, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of the ADVANTAGE AF clinical trial evaluating the use of the FARAPULSE™ Pulsed Field Ablation (PFA) System* and adjunctive use of the FARAPOINT™ PFA Catheter in...Read more
GALWAY, Ireland, April 24, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it has submitted 510(k) applications to the U.S. Food and Drug Administration (FDA) seeking clearance for an interoperable pump. FDA clearance of this pump would pave the way for system integration with a continuous glucose monitoring (CGM) sensor based on Abbott's most advanced CGM platform. The...Read more
Conference Call Scheduled for 9 a.m. EDT Today EXTON, Pa., April 24, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the first-quarter 2025 and declared a third-quarter 2025 dividend. First-Quarter 2025 Summary (comparisons to prior-year period) Net sales of $698.0 million increased 0.4%; organic net sales growth was 2.1%. Reported-diluted EPS of $1.23, compared...Read more
IRVINE, Calif. / Apr 23, 2025 / Business Wire / Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Mar. 31, 2025. Recent Highlights Q1 sales grew 6.2% to $1.41 billion, or 7.9% adjusted1 Q1 TAVR sales grew 3.8%; constant currency1 sales grew 5.4%, better than expected Q1 TMTT sales grew 58% to $115 million with meaningful contribution to Edwards' growth Q1 EPS of $0.622; adjusted1 EPS of...Read more
Year-over-year revenue grows 8%, operating profit up 14%, non-GAAP operating profit up 13% Operating cash flow of $579 million Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2025. Third Quarter 2025...Read more
Labcorp® Plasma Detect™ now available for clinical use to assess risk of recurrence in stage III colon cancer patients FDA-authorized liquid biopsy assay PGDx elio® plasma focus™ Dx now available to support treatment selection BURLINGTON, N.C., April 23, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the expansion of its precision oncology...Read more
Phasix™ ST Umbilical Hernia Patch Leverages Same Surgical Technique as Permanent Mesh Procedures FRANKLIN LAKES, N.J., April 23, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) and the commercial launch of Phasix™ ST Umbilical Hernia Patch, the first and only fully absorbable...Read more
MARLBOROUGH, Mass., April 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.663 billion during the first quarter of 2025, growing 20.9 percent on a reported basis, 22.2 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $674 million or $0.45 per...Read more
WALTHAM, Mass. / Apr 23, 2025 / Business Wire / Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 29, 2025. First Quarter Highlights First quarter revenue was $10.36 billion. First quarter GAAP diluted earnings per share (EPS) grew 15% to $3.98. First quarter adjusted EPS grew 1% to $5.15. Delivered very strong financial...Read more
SUNNYVALE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended March 31, 2025. Q1 Highlights Worldwide da Vinci procedures grew approximately 17% compared with the first quarter of 2024. The Company placed 367 da Vinci surgical systems,...Read more
WASHINGTON, April 22, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended March 28, 2025. Key First Quarter 2025 Results Net earnings were $1.0 billion, or $1.32 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.88. Revenues decreased 1.0% to $5.7 billion and non-GAAP core revenue was flat year-over-year. Operating...Read more
HemoSphere Alta™ Advanced Monitoring Platform with Predictive, Smart Algorithms Helps Clinicians Proactively Address Instability in Blood Flow and Pressure in Critical Situations FRANKLIN LAKES, N.J., April 21, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, has launched a new advanced hemodynamic monitoring platform with predictive, artificial intelligence (AI)...Read more
Latest approval expands Medtronic CGM portfolio in the U.S. GALWAY, Ireland, April 18, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the U.S. Food and Drug Administration (FDA) approval for the Simplera Sync™ sensor for use with the MiniMed™ 780G system. With this approval, the MiniMed™ 780G system now offers more flexibility for users of the company's most advanced insulin...Read more
CAIRO / Apr 18, 2025 / Business Wire / Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue technology have significantly improved long-term outcomes compared to those receiving non-RESILIA tissue bioprosthetic valves. For more than 65 years, Edwards has been the leader in heart valve innovations. To create a more durable heart...Read more
European certification for PD-L1 IHC 22C3 pharmDx to help gastric or GEJ adenocarcinoma patients for KEYTRUDA® therapy SANTA CLARA, Calif. / Apr 17, 2025 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR certification for the use as a Companion Diagnostic (CDx) to aid in the identification of gastric or gastroesophageal Junction (GEJ)...Read more
First-quarter GAAP diluted EPS of $0.76; adjusted diluted EPS of $1.09 First-quarter reported sales growth of 4.0 percent; organic sales growth of 6.9 percent or 8.3 percent when excluding COVID-19 testing-related sales1 Reported gross margin of 52.8 percent of sales; adjusted gross margin of 57.1 percent, which reflects a 140 basis point increase Reported operating margin of 16.3 percent of sales; adjusted operating margin of 21.0...Read more
Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of disease SAN DIEGO and CHICAGO, April 15, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to accelerate clinical adoption of next-generation sequencing tests...Read more
IRVINE, Calif. / Apr 14, 2025 / Business Wire / Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of patients with symptomatic (moderate-to-severe or severe) mitral regurgitation (MR) who are deemed unsuitable for surgery or transcatheter edge-to-edge (TEER) therapy. Leveraging the company’s SAPIEN technology, the SAPIEN M3...Read more
SUNNYVALE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Intuitive (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced that the U.S. Food & Drug Administration (FDA) cleared the company’s fully wristed SP SureForm 45 stapler for use with its da Vinci SP surgical system in thoracic, colorectal, and urologic procedures. Like its multiport...Read more
Dexcom G7 15 Day* is now cleared in the US for people age 18 years and above with diabetes. Now the longest lasting*,†,1 and most accurate1 CGM system, Dexcom G7 15 Day gives users the knowledge to better control diabetes. For people between the ages 2 to 18, Dexcom G7 remains the most accurate2 continuous glucose monitoring system. SAN DIEGO / Apr 10, 2025 / Business Wire / DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose...Read more
SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced its home sleep apnea test, NightOwl™, is now available across the United States. NightOwl is an FDA-cleared home sleep apnea test (HSAT) designed to offer healthcare providers a simplified, accurate, and efficient way to diagnose obstructive sleep...Read more
Clareon PanOptix Pro provides unprecedented 94% light utilization, resulting in half the light scatter of Clareon PanOptix1,2,§,* Clareon PanOptix Pro provides more uninterrupted light distribution across the full visual range, and is designed for better image contrast1,† Commercially available in the U.S. in May, Clareon PanOptix Pro is the next generation of the world’s leading trifocal IOL3-5,‡ GENEVA / Apr 02, 2025 / Business...Read more
Labcorp's pTau-217/Beta Amyloid 42 Ratio blood test meets the performance criteria to confirm amyloid pathology consistent with Alzheimer's disease BURLINGTON, N.C., April 2, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide launch of its pTau-217/Beta Amyloid 42 Ratio, a powerful new blood-based biomarker test to aid in the diagnosis of...Read more
BURNABY, British Columbia / Apr 01, 2025 / Business Wire / As of today, the Government of Saskatchewan’s expanded public coverage for continuous glucose monitoring (CGM) systems comes into effect. Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, applauds this decision as a testament to the government’s commitment to improving diabetes care. The expansion, which now...Read more
Expanding Thoracic Portfolio WARSAW, Ind., and ZUG, Switzerland, April 1, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE: ZBH and SIX: ZBH), a global medical technology leader, today announced its RibFix Advantage® Fixation System has received CE Mark certification – the first CE Mark for an intrathoracic rib fixation system. The RibFix Advantage Fixation System is intended for the thoracoscopic fixation,...Read more
CHICAGO / Mar 31, 2025 / Business Wire / Edwards Lifesciences (NYSE: EW) today announced new scientific evidence presented and published during the American College of Cardiology’s (ACC) Annual Scientific Session & Expo, addressing the critical needs of patients with structural heart disease. Without treatment, 1 in 10 patients experiencing symptoms of severe aortic stenosis (AS) may die within five weeks. However, the symptoms of...Read more
TRILUMINATE™ Pivotal data presented at the American College of Cardiology's Annual Scientific Session (ACC.25) and simultaneously published in Circulation show the Abbott TriClip system reduces heart failure hospitalizations The latest results highlight significant improvements in tricuspid regurgitation and quality of life through two years ABBOTT PARK, Ill., March 31, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced...Read more
GALWAY, Ireland and CHICAGO, March 30, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut™ transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve performance and durable...Read more
SUNNYVALE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ: ISRG), a global leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced the publication of two peer-reviewed studies in Surgical Endoscopy, on its first-of-its-kind Force Feedback technology incorporated in the da Vinci 5 surgical system. Force Feedback technology allows surgeons to feel the forces applied to tissue...Read more
Abbott's Volt™ PFA System is designed to provide a new therapy option for people battling heart rhythm disorders such as atrial fibrillation Pulsed field ablation – or PFA – uses high energy electrical pulses for ablation procedures that may offer benefits to targeting and treating tissue in the heart Abbott's Volt PFA System is designed to overcome limitations of existing PFA systems, providing improved workflows and a clearer...Read more
Leverages Alcon’s global scale with Aurion’s cell therapy expertise to accelerate U.S. Phase 3 development in fall of 2025 Aurion’s lead asset received Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation from the U.S. Food and Drug Administration (FDA) Positions Alcon at the leading edge of biopharma applications in ophthalmology with the potential to advance the first-ever corneal cell therapy...Read more
Clareon Vivity IOL provides an extended range of vision from distance to functional near with a monofocal visual disturbance profile1-3µ‖ Vivity, the world’s leading EDOF, is now available on Alcon’s Clareon material, providing presbyopia correction with exceptional† clarity and predictable refractive outcomes1,4-7 CE Marked countries will begin commercial rollout of Clareon Vivity and Clareon Vivity Toric from early Q2 2025; also...Read more
Coronary Artery Disease (CAD) is the most common heart disease and most frequent cause of death in the U.S., with over 20 million adults affected by this condition Abbott's investigational Coronary Intravascular Lithotripsy (IVL) System offers a new potential treatment by using sound pressure waves to treat arterial calcium blockages Abbott offers a comprehensive vascular portfolio of technologies designed to assess, treat and manage...Read more
Innovative technology supports testing of accuracy and reliability in Autolus Therapeutics’ recently approved CAR T therapy AUCATZYL® SANTA CLARA, Calif. / Mar 24, 2025 / Business Wire / Agilent Technologies Inc. (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ FDA approval for AUCATZYL®, a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the xCELLigence...Read more
FRANKLIN LAKES, N.J., March 20, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the first patient treated in an Investigational Device Exemption (IDE) clinical trial intended to advance BD's efforts to achieve Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the use of GalaFLEX LITE™ Scaffold in decreasing capsular...Read more
Adoption allows ICON to take full advantage of the Medidata “Data Experience,” leveraging AI to unify data sources, standardize outputs, and reduce reconciliation efforts NEW YORK / Mar 20, 2025 / Business Wire / Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced that ICON plc, (NASDAQ: ICLR) a world-leading clinical research organization (CRO) powered by...Read more
Creates one of the largest, most comprehensive clinical genomic datasets of its kind; multiomic data to be added in next phase of program AGD members are using the population-level insights to uncover novel drug targets SAN DIEGO, March 19, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) and Nashville Biosciences, LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary...Read more
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark meta-analysis in The Lancet Respiratory Medicine, demonstrating that CPAP therapy significantly reduces the risk of death for people with obstructive sleep apnea (OSA). Analyzing data from over 1 million sleep apnea...Read more
WALTHAM, Mass. / Mar 18, 2025 / Business Wire / Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced the launch of the Thermo Scientific Vulcan™ Automated Lab, a groundbreaking solution designed to drive a new era of process development and control in semiconductor manufacturing. The seamlessly integrated system is designed to enhance productivity, increase yield and reduce...Read more
Transaction to extend Labcorp's leadership in oncology and expand access to the company's high-quality clinical laboratory services BURLINGTON, N.C. and MIAMI, March 11, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announced today that they have entered into an...Read more
Company | Change | Last Trade |
---|---|---|
Mettler-Toledo | 12.12 1.00 | $1,218.65 |
West Pharmaceutical | 5.70 2.59 | $226.18 |
Stryker | 2.55 0.65 | $392.05 |
Zimmer Biomet | 1.73 1.85 | $95.20 |
Labcorp | 1.62 0.63 | $259.07 |
DexCom | 1.11 1.33 | $84.87 |
Insulet | 0.95 0.32 | $297.46 |
Becton Dickinson | 0.87 0.50 | $175.50 |
Intuitive | 0.83 0.16 | $528.13 |
Edwards Lifesciences | 0.80 1.05 | $77.19 |
Boston Scientific | 0.55 0.54 | $102.96 |
Medtronic | 0.42 0.47 | $89.00 |
Agilent Technologies | 0.29 0.24 | $121.30 |
Danaher | 0.28 0.14 | $200.96 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE